Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.

JACC. Heart failure - 1 Aug 2023

Kosiborod Mikhail N, Abildstrøm Steen Z, Borlaug Barry A, Butler Javed, Christensen Louise, Davies Melanie, Hovingh Kees G, Kitzman Dalane W, Lindegaard Marie L, Møller Daniél Vega, Shah Sanjiv J, Treppendahl Marianne Bach, Verma Subodh, Petrie Mark C

Abstract excerpt

BACKGROUND: The majority of patients with heart failure with preserved ejection fraction (HFpEF) have the obesity phenotype, but no therapies specifically targeting obesity in HFpEF exist. OBJECTIVES: The aim of this study was to describe the design and baseline characteristics of 2 trials of semaglutide, a glucagon-like peptide-1 receptor agonist, in patients with the obesity HFpEF phenotype: STEP-HFpEF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes Mellitus, Type 2
Share to Diuretics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Heart Failure

Share to Obesity

Share to Phenotype

Share to Stroke Volume

Share to Ventricular Function, Left

Source

Identifiers

PMID: 37294245
DOI: 10.1016/j.jchf.2023.05.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.PMID 37294245Read ↗

Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.Semantic proximity Read ↗

One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.Semantic proximity Read ↗

Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction.Semantic proximity Read ↗

Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials.Semantic proximity Read ↗

Targeting Metabolic Dysfunction and Inflammation with Sotagliflozin Reverses Diastolic Dysfunction in Experimental HFpEFSemantic proximity Read ↗

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Semantic proximity Read ↗

Primary heart failure with preserved ejection fraction: The intertwined pathophysiology and treatment of some of the most relevant phenotypes.Semantic proximity Read ↗

Does Characterization of Phenotypic Heterogeneity Provide Mechanistic Insights or Influence the Response to Treatment? Experience in Positive and Neutral Trials in Patients With Heart Failure and a Preserved Ejection Fraction.Semantic proximity Read ↗

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity Read ↗

Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.Semantic proximity Read ↗

Salt-inducible kinase inhibition promotes weight loss and improves the diastolic function of obesity-related heart failure with preserved ejection fraction in miceSemantic proximity Read ↗

Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.